Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046032 Monotherapy and Combination Therapy in Advanced Malignancies
NCT06870487Phase 1Terminated
- Sponsor
- Pfizer
- Start
- May 2025
- Primary completion
- Apr 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of PF-08046032 in peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL), classical Hodgkin lymphoma (cHL) and 3 more (3 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities up to 28 days, Adverse Events up to 90 days and 2 more. Started May 2025; status: terminated.
02
Drugs
PF-08046032
03
Conditions
peripheral T-cell lymphoma (PTCL)diffuse large B-cell lymphoma (DLBCL)classical Hodgkin lymphoma (cHL)head and neck squamous cell carcinoma (HNSCC)melanoma
Beyond the preview
Go deeper on NCT06870487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06870487.